drugset / Trial / NCT00133107
Safety and Effectiveness of Efalizumab to Treat Oral Lichen Planus
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This study is to determine whether efalizumab 1.0mg/kg given by subcutaneous injection for 12 weeks is effective in treating oral lichen planus. This is a 20 week, single center, open-label pilot study to enroll 5 subjects.
Timeline
- Start
- 2005-01
- Primary completion
- 2005-11
- Completion
- 2005-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | efalizumab | Monoclonal antibody | 1 mg/kg | Subcutaneous |